Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 ...
Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF
Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...
Some clinicians prefer aspirin when balancing bleeding risk with the indication for an anticoagulant, Barnes said, reasoning ...
Apixaban significantly reduces stroke risk in people with subclinical atrial fibrillation and prior stroke history.
Afib patients with chronic inflammation have a higher risk of stroke and embolism. Inflammation is also tied to hardening of the blood vessels (called atherosclerosis) that can lead to stroke and ...
This article suggests the need to reconsider the benefits of using aspirin in stroke prevention ... in the production of this manuscript. Atrial fibrillation (AF) is the most common cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback